Monographie - Eptifibatide - Stabilis 4.0

Poslední aktualizace :
08/05/2024

Antikoaguliantas

Eptifibatide

Įpurškimas

Tirpalų stabilumas

Mišinių stabilumas

Stabilumą lemiantys veiksniai

Suderinamumas

Leidimo būdai

Bibliografija

Pdf

Cheminė sandara

Prekinis pavadinimas

Prekinis pavadinimas

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eptifab	Indija
Eptifibatida	Ispanija, Rumunija
Eptifibatide	Belgija, Didžioji Britanija, Kanada
Fletabolus	Indija
Integrilin	Airija, Argentina, Australija, Austrija, Belgija, Čilė, Danija, Didžioji Britanija, Egiptas, Graikija, Iranas, Islandija, Ispanija, Italija, Japonija, Jungtinės Amerikos Valstijos, Jungtiniai Arabų Emyratai, Kanada, Lenkija, Liuksemburgas, Malaizija, Naujojoje Zelandijoje, Norvegija, Olandija, Portugalija, Prancūzija, Rumunija, Švedija, Šveicarija, Vengrija, Vokietija

Bibliografija

Įpurškimas

Bibliografija : Eptifibatide

	Tipas	Leidinys
1611	Žurnalas	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1713	Žurnalas	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
2004	Žurnalas	Patel K, Hursting MJ. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 1381-1384.
2108	Žurnalas	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2346	Žurnalas	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
3827	Plakatas	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Plakatas	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Plakatas	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3934	Laboratorija	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
4055	Žurnalas	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Žurnalas	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433	Žurnalas	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.

Mentions Légales